Abstract: Soft tissue sarcoma （STS）constitutes a heterogeneous group of rare solid tumors of mesenchymal cell origin with different clinicopathological features. The outcome of patients with advanced STS and the efficacy of chemotherapy are poor. Therefore， new therapeutic strategies are desperately needed to improve treatment efficacy. With deeper understanding of the biological behavior of STS， several emerging anti-angiogenesis agents are used in clinic and have achieved good efficacy， which may bring breakthrough to the treatment of STS and improve the prognosis. In this review， we will discuss the current advances in anti-angiogenesis agents for STS.